Document:

<PAGE>
                                                                    EXHIBIT 10.2

                          NORTHFIELD LABORATORIES INC.

                            STOCK OPTION GRANT LETTER

            Pursuant to terms of the Northfield Laboratories Inc. 2003 Equity
Compensation Plan (the "Plan"), this letter will evidence the award by
Northfield Laboratories Inc. (the "Company") to __________________________ (the
"Recipient") of an option (the "Option") to purchase up to __________ shares
(the "Option Shares") of the Company's Common Stock, par value $.01 per share,
at an exercise price of $__________ per share.

            The Option will in all respects be governed by and construed in
accordance with the terms and conditions of the Plan, as it is currently in
effect and as it may be amended in the future from time to time, which terms and
conditions are incorporated herein by reference and made a part hereof. The
Recipient hereby acknowledges receipt of a copy of the Plan as in effect as of
the date of this letter.

            In addition to the terms and conditions of the Plan, the Option
awarded hereby will be subject to the following terms and conditions:

            1. The Option will be deemed to be a Non-Qualified Stock Option as
      defined under the Plan.

            2. Except as otherwise expressly provided herein, the Option may be
      exercised by the Recipient in whole or in part at any time and from time
      to time during the period com- mencing as of the first anniversary of the
      date of this letter and ending on the tenth anniversary of the date of
      this letter.

            3. The Option will be subject to the following vesting requirements.
      As of the first anniversary of the date of this letter and provided that
      the Recipient continues as of such date to be employed by the Company as a
      officer or employee, the Option will be deemed vested and immediately
      exercisable as to 25% of the Option Shares. As of the second anniversary
      of the date of this letter and provided that the Recipient continues as of
      such date to be employed by the Company as an officer or employee, the
      Option will be deemed vested and immediately exercisable as to 50% of the
      Option Shares. As of the third anniversary of the date of this letter and
      provided that the Recipient continues as of such date to be employed by
      the Company as an officer or employee, the Option will be deemed vested
      and immediately exercisable as to 75% of the Option Shares. As of the
      fourth anniversary of the date of this letter and provided that the
      Recipient continues as of such date to be employed by the Company as an
      officer or employee, the Option will be deemed vested and immediately
      exercisable as to 100% of the Option Shares.

            4. Unless otherwise determined by a least two-thirds of the
      individuals who, as of the date of this letter, constitute the Board of
      Directors of the Company (the "Incumbent Board"), vesting of the
      Recipient's right to exercise the Option as provided in paragraph 3 will
      accelerate upon the occurrence of a Change in Control of the Company. For
      this purpose, a "Change in Control" will mean a change in control of a
      nature that would be required to be reported in response to Item 1(a) of
      the Current Report on Form 8-K, as in effect as of the date of this
      Agreement, promulgated pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934, as amended (the "Securities Exchange Act"), whether
      or not the Company is then subject to the reporting requirements of the
      Securities Exchange
<PAGE>

      Act; provided that, without limitation, such a change in control will be
      deemed to have occurred if (a) there is consummated any sale, lease,
      exchange or other transfer (in one transaction or a series of related
      transactions) of all or substantially all of the Company's assets, (b) the
      stockholders of the Company approve any plan or proposal of liquidation or
      dissolution of the Company, (c) there is consummated any consolidation or
      merger of the Company in which the Company is not the surviving or
      continuing corporation, or pursuant to which shares of the Company's
      Common Stock would be converted into cash, securities or other property,
      other than a merger of the Company in which the holders of the Company's
      Common Stock immediately prior to the merger have, directly or indirectly,
      at least an 80% ownership interest in the outstanding Common Stock of the
      surviving corporation immediately after the merger, (d) any "person" or
      "group" (as such terms are used in Section 13(d) and 14(d) of the
      Securities Exchange Act) becomes the "beneficial owner" (as defined in
      Rule 13d-3 under the Securities Exchange Act), directly or indirectly, of
      securities of the Company representing 30% or more of the combined voting
      power of the Company's then outstanding voting securities ordinarily
      having the right to vote for the election of directors (unless such
      acquisition of beneficial ownership is approved by a majority of the
      Incumbent Board) or (e) individuals who, as of the date of this Agreement,
      constitute the Incumbent Board cease for any reason to constitute a
      majority of the Board of Directors of the Company.  Any individual
      becoming a director subsequent to the date of this letter whose election,
      or nomination for election by the Company's stockholders, was approved by
      a vote of at least three-quarters of the directors comprising the
      Incumbent Board (other than an election or nomination of an individual
      whose initial assumption of office is in connection with an actual or
      threatened election contest relating to the directors of the Company, as
      such terms are used in Rule 14a-11 of Regulation 14A promulgated under the
      Securities Exchange Act) will be, for purposes hereof, considered as
      though such individual was a member of the Incumbent Board.
      Nothwithstanding the foregoing, a public or private sale or issuance of
      equity securities, or securities exercisable or exchangeable for or
      convertible into equity securities, of the Company for its own account or
      for the account of any holder of the Company's equity securities as of the
      date hereof will not result in a "change in control" for purposes of this
      letter if such sale or issuance is approved by at least three-quarters of
      the directors comprising the Incumbent Board.

            5.  The Recipient will have no right to acquire any shares of the
      Company's Common Stock pursuant to the Option except to the extent that
      the Recipient's rights under      the Option have deemed to have vested as
      provided herein.  The rights of the Recipient with respect to the unvested
      portion of the Option will terminate in all respects as of the date the
      Recipient's employment by the Company as an officer or employee ceases for
      any reason, and no further vesting will occur after such date.

            6.  If the Recipient's employment by the Company as a officer or
      employee ceases as the result of the Recipient's death or Disability, then
      the vested portion of the Option will thereafter be exercisable by the
      Recipient, or his or her executor or other legal representative, for a
      period of one year.

                                       2

<PAGE>
            7.  If the employment of the Recipient by the Company as an officer
      or employee is terminated by the Company other than for Cause, then the
      vested portion of the Option will thereafter be exercisable by the
      Recipient for a period of 90 days.

            8. If the employment of the Recipient by the Company as an officer
      or employee ceases for any other reason, then the Option will be deemed to
      have terminated and the Recipient will have no further rights thereunder.

            9. Any portion of the Option not exercised prior to the expiration
      of the periods described in paragraphs 6 and 7 will be deemed forfeited by
      the Recipient.

            10. For purposes hereof, "Cause" for the termination of the
      Recipient's employment with the Company as an officer or employee will be
      deemed to exist if the Recipient has been convicted of a felony or if the
      Board of Directors of the Company determines that the Recipient has (a)
      intentionally and continually failed to perform in all material respects
      the Recipient's reasonably assigned duties with the Company (other than a
      failure resulting from the Recipient's Disability) which failure has
      continued for a period of at least 30 days after a written notice of
      demand for performance has been delivered to the Recipient specifying the
      manner in which the Recipient has failed in all material respects to so
      perform or (b) intentionally engaged in conduct which is demonstrably and
      materially injurious to the Company.  For purposes hereof, "Disability"
      means a physical or mental disability or illness which substantially
      impairs the Recipient's ability to perform his or her regular duties with
      the Company for a period in excess of 180 consecutive days or for a period
      in excess of 270 days in any 365-day period.

            11. Notwithstanding any provision herein to the contrary, the
      Recipient may not offer, sell or otherwise dispose of any Option Shares in
      a way which would (a) require the Company to file any registration
      statement with the Securities and Exchange Commission (or any similar
      filing under state law) or to amend or supplement any such filing or (b)
      violate or cause the Company to violate the Securities Act of 1933, as
      amended, the rules and regulations promulgated thereunder or any other
      state or federal law.

            Any questions regarding this letter or the terms and conditions of
the Plan may be directed to Jack J. Kogut, the Company's Sr. Vice President -
Finance, Secretary and Treasurer.

DATED:  __________, 2003                   NORTHFIELD LABORATORIES INC.

                                          BY
                                             ----------------------------------
                                                MEMBER
                                                COMPENSATION COMMITTEE

                                       3<PAGE>
                                                                    EXHIBIT 10.3

                          NORTHFIELD LABORATORIES INC.

                            STOCK OPTION GRANT LETTER

      Pursuant to terms of the Northfield Laboratories Inc. 2003 Equity
Compensation Plan (the "Plan"), this letter will evidence the award by
Northfield Laboratories Inc. (the "Company") to _________________ (the
"Recipient") of an option (the "Option") to purchase up to ____________shares
(the "Option Shares") of the Company's Common Stock, par value $.01 per share,
at an exercise price of $_____________ per share.

      The Option will in all respects be governed by and construed in accordance
with the terms and conditions of the Plan, as it is currently in effect and as
it may be amended in the future from time to time, which terms and conditions
are incorporated herein by reference and made a part hereof. The Recipient
hereby acknowledges receipt of a copy of the Plan as in effect as of the date of
this letter.

      In addition to the terms and conditions of the Plan, the Option awarded
hereby will be subject to the following terms and conditions:

            1. The Option will be deemed to be a Non-Qualified Stock Option as
      defined under the Plan.

            2. Except as otherwise expressly provided herein, the Option may be
      exercised by the Recipient in whole or in part at any time and from time
      to time during the period commencing as of the date of this letter and
      ending on the tenth anniversary of the date of this letter. The Option
      will be deemed fully vested and exercisable as of the date of this letter.

            3. If the Recipient's service as a director of the Company ceases as
      the result of the Recipient's death or Disability, then the Option will
      thereafter be exercisable by the Recipient, or his or her executor or
      other legal representative, for a period of one year form the date of
      disability or death.

            4. If the Recipient's service as a director of the Company ceases as
      a result of the failure of the Recipient to be nominated to serve as a
      director of the Company or as a result of the failure of the Company's
      stockholders to elect the Recipient as a director of the Company (provided
      that the Recipient has agreed to be nominated as a director), then the
      Option will thereafter be exercisable by the Recipient for a period of 90
      days from the date Recipient's service as a director of the Company
      ceases.

            5. If the Recipient's service as a director of the Company ceases
      for any other reason, then the Option will be deemed to have terminated
      and the Recipient will have no further rights hereunder.

            6. Any portion of the Option not exercised prior to the expiration
      of the periods described in paragraphs 2, 3, 4 and 5 will be deemed
      forfeited by the Recipient

<PAGE>

            7. For purposes hereof, "Disability" means a physical or mental
      disability or illness which substantially impairs the Recipient's ability
      to perform his or her regular duties with the Company for a period in
      excess of 180 consecutive days or for a period in excess of 270 days in
      any 365-day period.

            8. Nothwithstanding any provision herein to the contrary, the
      Recipient may not offer, sell or otherwise dispose of any Option Shares in
      a way which would (a) require the Company to file any registration
      statement with the Securities and Exchange Commission (or any similar
      filing under state law) or to amend or supplement any such filing or (b)
      violate or cause the Company to violate the Securities Act of 1933, as
      amended, the rules and regulations promulgated thereunder or any other
      state or federal law.

      Any questions regarding this letter or the terms and conditions of the
Plan may be direct to Jack J. Kogut, the Company's Senior Vice President and
Chief Financial Officer.

                                        NORTHFIELD LABORATORIES INC.

DATED:  ____________, 2004              BY:
                                           --------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]